Instil Bio (TIL) Receivables - Other (2020 - 2026)

Instil Bio (TIL) posted quarterly Receivables - Other of $28000.0 for Q1 2026, down 96.7% quarter-over-quarter from $848000.0 in Q4 2025.

Instil Bio (TIL) Receivables - Other (2020 - 2026) Analysis & Trends

Instil Bio's Receivables - Other history runs 6 years deep, the most recent figure standing at $28000.0 for Q1 2026.

In Q1 2026, Receivables - Other changed N/A year-over-year to $28000.0; the TTM figure through Mar 2026 stood at $28000.0 (changed N/A YoY), while the FY2025 annual figure was $848000.0, down 67.66% from the prior year.
Receivables - Other for Q1 2026 stood at $28000.0, down from $848000.0 in the prior quarter.
The five-year high for Receivables - Other was $3.6 million in Q4 2023, with the low at $28000.0 in Q1 2026.
The 4-year median for Receivables - Other is $848000.0 (2025), against an average of $1.7 million.
The sharpest annual moves came in 2024 and 2025: Receivables - Other fell 28.03% in 2024, then sank 71.08% in 2025.
Instil Bio's Receivables - Other stood at $3.6 million in 2023, then dropped by 28.03% to $2.6 million in 2024, then tumbled by 67.66% to $848000.0 in 2025, then sank by 96.7% to $28000.0 in 2026.
Business Quant data shows TIL's Receivables - Other at $28000.0 in Q1 2026, $848000.0 in Q4 2025, and $843000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Instil Bio	50.29 Mn	50.29 Mn	-

Download Data